Current and historical daily PE Ratio for Vanda Pharmaceuticals Inc (
STU:VM4
) from 2006 to Jun 15 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Vanda Pharmaceuticals stock (STU:VM4) PE ratio as of Jun 15 2024 is 0.
More Details
Vanda Pharmaceuticals Inc (STU:VM4) PE Ratio (TTM) Chart
Vanda Pharmaceuticals Inc (STU:VM4) PE Ratio (TTM) Historical Data
View and export this data going back to 2006. Start your Free Trial
Total 1261
- 1
- 2
- 3
- 4
- 5
- 6
- 15
Vanda Pharmaceuticals PE Ratio (TTM) Historical Data | |||
---|---|---|---|
Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
2024-06-15 | At Loss | 2024-04-12 | At Loss |
2024-06-14 | At Loss | 2024-04-11 | At Loss |
2024-06-13 | At Loss | 2024-04-10 | At Loss |
2024-06-12 | At Loss | 2024-04-09 | At Loss |
2024-06-11 | At Loss | 2024-04-08 | At Loss |
2024-06-10 | At Loss | 2024-04-05 | At Loss |
2024-06-07 | At Loss | 2024-04-04 | At Loss |
2024-06-06 | At Loss | 2024-04-03 | At Loss |
2024-06-05 | At Loss | 2024-04-02 | At Loss |
2024-06-04 | At Loss | 2024-03-28 | At Loss |
2024-06-03 | At Loss | 2024-03-27 | 72.7 |
2024-05-31 | At Loss | 2024-03-26 | 72.7 |
2024-05-30 | At Loss | 2024-03-25 | 72.2 |
2024-05-29 | At Loss | 2024-03-22 | 72.7 |
2024-05-28 | At Loss | 2024-03-21 | 70.6 |
2024-05-27 | At Loss | 2024-03-20 | 69.4 |
2024-05-24 | At Loss | 2024-03-19 | 70.6 |
2024-05-23 | At Loss | 2024-03-18 | 69.8 |
2024-05-22 | At Loss | 2024-03-15 | 71.4 |
2024-05-21 | At Loss | 2024-03-14 | 71.4 |
2024-05-20 | At Loss | 2024-03-13 | 70.6 |
2024-05-17 | At Loss | 2024-03-12 | 72.2 |
2024-05-16 | At Loss | 2024-03-11 | 74.7 |
2024-05-15 | At Loss | 2024-03-08 | 72.2 |
2024-05-14 | At Loss | 2024-03-07 | 70.6 |
2024-05-13 | At Loss | 2024-03-06 | 73.5 |
2024-05-10 | At Loss | 2024-03-05 | 77.5 |
2024-05-09 | At Loss | 2024-03-04 | 79.6 |
2024-05-08 | At Loss | 2024-03-01 | 85.3 |
2024-05-07 | At Loss | 2024-02-29 | 83.3 |
2024-05-06 | At Loss | 2024-02-28 | 86.5 |
2024-05-03 | At Loss | 2024-02-27 | 84.9 |
2024-05-02 | At Loss | 2024-02-26 | 81.6 |
2024-04-30 | At Loss | 2024-02-23 | 82.9 |
2024-04-29 | At Loss | 2024-02-22 | 80.8 |
2024-04-26 | At Loss | 2024-02-21 | 81.2 |
2024-04-25 | At Loss | 2024-02-20 | 82.0 |
2024-04-24 | At Loss | 2024-02-19 | 82.0 |
2024-04-23 | At Loss | 2024-02-16 | 82.9 |
2024-04-22 | At Loss | 2024-02-15 | 81.6 |
2024-04-19 | At Loss | 2024-02-14 | 80.0 |
2024-04-18 | At Loss | 2024-02-13 | 81.2 |
2024-04-17 | At Loss | 2024-02-12 | 83.3 |
2024-04-16 | At Loss | 2024-02-09 | 77.1 |
2024-04-15 | At Loss | 2024-02-08 | 68.6 |
Vanda Pharmaceuticals Inc (STU:VM4) PE Ratio (TTM) Comparison
Company | Market Cap(Mil) | PE Ratio (TTM) |
---|
Business Description
Business Description
![Vanda Pharmaceuticals Inc Vanda Pharmaceuticals Inc logo](https://static.gurufocus.com/logos/0C00000KOY.png?14)
Vanda Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US9216591084
Share Class Description:
STU:VM4: Ordinary SharesDescription
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS), Fanapt for the treatment of schizophrenia and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from HETLIOZ product sales.